139P A study of cadonilimab combined with anlotinib in advanced NSCLC patients after systemic therapy failure and resistance to Anti–PD-(L)1 antibody treatment
Year: 2025
Type: article
Abstract: Resistance to immunotherapy remains an urgent clinical challenge in advanced non-small cell lung cancer (NSCLC). For patients with acquired resistance after multiline therapy, immunotherapy rechallenge represents a potential strategy, but optimal combinations lack robust evidence. The combination of immunotherapy with antiangiogenic therapy is emerging as a trend. Cadonilimab plus anlotinib has shown potential efficacy in this setting.
Source: Immuno-Oncology Technology
Institution: Affiliated Hospital of North Sichuan Medical College
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,340
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, F. Hoffmann-La Roche, Multinational Association of Supportive Care in Cancer, Les Laboratories Pierre Fabre, Mersana Therapeutics, Seagen, European Society of Cardiology, Novo Nordisk, Fondazione Umberto Veronesi, European Society for Medical Oncology, Servier, Genentech, Daiichi Sankyo Europe
Award: G494956506
OpenAlex ID: W7117294201
FWCI:
Cites:
Cited by:
Related to: